Predicting the outcome of ankylosing spondylitis therapy

Predicting the outcome of ankylosing spondylitis therapy

Objectives To create a model that provides a potential basis for candidate selection for anti-tumour necrosis factor (TNF) treatment by predicting future outcomes relative to the current disease profile of individual patients with ankylosing spondylitis (AS). Methods ASSERT and GO–RAISE trial data (...

Uloženo v:

Podrobná bibliografie
Hlavní autoři:	Nathan Vastesaeger, Désirée van der Heijde, Robert D. Inman, Yanxin Wang, Atul Deodhar, Benjamin Hsu, Mahboob U. Rahman, Ben A. C. Dijkmans, Piet Geusens, Bert Vander Cruyssen, Eduardo Collantes‐Estévez, Joachim Sieper, Jürgen Braun
Médium:	Artigo
Jazyk:	angličtina
Vydáno:	2011
On-line přístup:	https://doi.org/10.1136/ard.2010.147744 https://ard.bmj.com/content/annrheumdis/70/6/973.full.pdf
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky

Predicting the outcome of ankylosing spondylitis therapy
Autor: Vastesaeger, Nathan, a další
Vydáno: (2011)

Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery
Autor: Bert Vander Cruyssen, a další
Vydáno: (2009)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
Autor: van der Heijde, Désirée, a další
Vydáno: (2019)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
Autor: Désirée van der Heijde, a další
Vydáno: (2018)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
Autor: Braun, Jürgen, a další
Vydáno: (2011)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
Autor: Jürgen Braun, a další
Vydáno: (2011)

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab
Autor: Wagner, Carrie, a další
Vydáno: (2011)

Ankylosing spondylitis: an overview
Autor: Joachim Sieper, a další
Vydáno: (2002)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
Autor: Deodhar, Atul, a další
Vydáno: (2015)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
Autor: Atul Deodhar, a další
Vydáno: (2014)

Anti-tumour necrosis factor α therapy for ankylosing spondylitis: international experience
Autor: Braun, J, a další
Vydáno: (2002)

The Effect of Golimumab Therapy on Disease Activity and Health-related Quality of Life in Patients with Ankylosing Spondylitis: 2-year Results of the GO-RAISE Trial
Autor: Désirée van der Heijde, a další
Vydáno: (2014)

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Autor: Dominique Baeten, a další
Vydáno: (2015)

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis
Autor: Jürgen Braun, a další
Vydáno: (2005)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
Autor: Jürgen Braun, a další
Vydáno: (2011)

Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis
Autor: Jürgen Braun, a další
Vydáno: (2023)

Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study
Autor: Inman, Robert D., a další
Vydáno: (2016)

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study
Autor: Xenofon Baraliakos, a další
Vydáno: (2023)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
Autor: Braun, Jürgen, a další
Vydáno: (2014)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
Autor: Jürgen Braun, a další
Vydáno: (2013)

The epidemiology of ankylosing spondylitis and the commencement of anti‐TNF therapy in daily rheumatology practice
Autor: Cruyssen, Bert Vander, a další
Vydáno: (2007)

The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice
Autor: Bert Vander Cruyssen, a další
Vydáno: (2007)

Spinal Radiographic Changes in Ankylosing Spondylitis: Association with Clinical Characteristics and Functional Outcome
Autor: Annelies Boonen, a další
Vydáno: (2009)

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
Autor: Braun, Jürgen, a další
Vydáno: (2018)

The epidemiology of osteoporosis and fractures in ankylosing spondylitis
Autor: Sambrook, Philip N., a další
Vydáno: (2012)

The epidemiology of osteoporosis and fractures in ankylosing spondylitis
Autor: Philip N. Sambrook, a další
Vydáno: (2012)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
Autor: Braun, Jürgen, a další
Vydáno: (2011)

ASAS/EULAR recommendations for the management of ankylosing spondylitis
Autor: Zochling, J, a další
Vydáno: (2006)

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
Autor: Désirée van der Heijde, a další
Vydáno: (2022)

Etanercept in the Longterm Treatment of Patients With Ankylosing Spondylitis
Autor: Ben A. C. Dijkmans, a další
Vydáno: (2009)

Ankylosing spondylitis: an overview
Autor: Sieper, J, a další
Vydáno: (2002)

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis
Autor: Sudha Visvanathan, a další
Vydáno: (2008)

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
Autor: Braun, J, a další
Vydáno: (2011)

Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches.
Autor: Jürgen Braun, a další
Vydáno: (2002)

Definition of disease duration in ankylosing spondylitis: reassessing the concept
Autor: Davis, J C, a další
Vydáno: (2006)

Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis
Autor: Désirée van der Heijde, a další
Vydáno: (2007)

Staging of patients with ankylosing spondylitis: a preliminary proposal
Autor: Braun, J, a další
Vydáno: (2002)

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
Autor: Désirée van der Heijde, a další
Vydáno: (2008)

Determinants of hyperkyphosis in patients with ankylosing spondylitis
Autor: Vosse, D, a další
Vydáno: (2006)

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
Autor: Jürgen Braun, a další
Vydáno: (2016)